We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| 3Legs Resources | 3LEG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.3175 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.3175 | 0.3175 |
| Top Posts |
|---|
Posted at 21/3/2016 13:14 by wiseacre An experimental cancer drug discovered at Oxford university is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group.SalvaRX has been set up with backing from Jim Mellon, the Isle of Man-based investor, as an incubator for early-stage cancer drug developers. More On this topic Call for tighter controls for drug trials Anjana Ahuja Ditching your birth identity Immune cell breakthrough in cancer fight Bioelectrics industry is one to watch IN Pharmaceuticals Valeant is the latest troubled roll-up to unravel Witty’s tenure at GSK divides opinion Analysts bullish as Valeant struggled Witty defends GSK strategy to the end Its first asset is iOx Therapeutics which is working on treatments using so-called natural killer T-cells to attack tumours. SalvaRX’s chief executive, Ian Walters, and its chief scientific officer, Robert Kramer, were both senior members of the team that put BMS at the forefront of a new class of cancer drugs called immunotherapies. These medicines, which harness the immune system to destroy tumours, are widely seen as the most important cancer breakthrough for decades and have been tipped to generate tens of billions of dollars in annual sales for the pharma industry. SalvaRX will scour academia and the biotech sector for novel immunotherapies and deploy capital and expertise to develop them. The company’s shares are due to begin trading on London’s junior Aim market on Tuesday after a reverse takeover of 3Legs Resources, a shell company backed by Mr Mellon which was previously engaged in a failed search for shale gas in Poland. Mr Mellon, whose wealth was estimated at £850m in last year’s Sunday Times rich list, made his fortune in mining but also invests in life sciences. SalvaRX raised just under £2m in a share placement as part of its reversal into the Aim shell and Dr Walters said the company planned a more substantial fundraising with institutional investors in due course. See Today's FT: The company owns 60 per cent of iOx with the rest held by Oxford university and Ludwig Cancer Research, a global network of leading cancer scientists. IOx’s so-called iNKT agonist drugs have shown promise in animals and Dr Walters said the first clinical trials in humans would start soon, financed by Oxford. Dr Walters acknowledged that cancer immunotherapy had become a crowded field but insisted there was still plenty of untapped science — especially in Europe — beyond the “checkpoint inhibitors” that have attracted most investment so far. “Eighty-five per cent of the industry is focusing on checkpoints and antibodies. We are focusing on the other areas where there is a lot of white space,” he said. “The science is advancing exponentially so there is so much more to come. In the long term this is about turning cancer into a chronic disease.” |
Posted at 04/3/2016 08:44 by sweet karolina I have now read the full 116 page admission document.It is a good deal for current shareholders. The placing has been done at the same price as the reverse - it will not have gone to bucket shops looking to make a quick turn. Shareholders should vote for all the EGM resolutions and get the company back trading again. You do not need to read guardian articles, there is an excellent in depth report on the clinical situation in the admission document. When trading recommences, I would expect there to be not a lot of liquidity in the stock. Newsflow in the early years to be infrequent and not particularly exciting. I would expect that more shares will need to be issued in about 12 months time, or earlier if another acquisition is to be made. I would put the chances of long term investors losing most or all of their money at 90% with a 9% chance of not losing too much / making a small profit and a 1% chance of making a decent profit, but that will be a good few years down the line. Whilst I fully support the work iOx are doing, the risk reward balance does not work for me as an investor. Those are my considered views having read the document and having no axes to grind either way. |
Posted at 04/11/2015 08:02 by edcrane Shares suspended but if investors are excited about this RTO then remember Vela Technologies owns just under 4% of 3Legs |
Posted at 18/8/2015 11:16 by 5baggersrus Mann Bioinvest Launches Pathfinder Fund Targeting Life Science Growth FirmsSt Helier, Jersey/Douglas, Isle of Man – August 4, 2015 – Mann Bioinvest, the Isle of Man-headquartered specialist life science advisory company chaired by renowned investor Jim Mellon, has launched a new global investment fund focused on small-cap and private companies in the therapeutic sector. Mann Bio Pathfinder IC (MBP)– is the firm’s second life sciences vehicle and will be managed by chief investment officer Andy Smith, whose track record in the sector is well established – Smith’s existing fund with Mann Bioinvest, the Magna Biopharma Income Fund (MBIF), is up over 50% in the 19 months since inception. “We believe the life science sector is entering a secular growth phase that will eclipse the golden age of pharmaceutical drug development in the 1990s,” says Smith. “Forty one new drugs were approved by the Federal Drug Administration in 2014, an 18-year high.” Small-cap and Private Companies Undervalued Although there has been a run-up in valuations of mid- and large-cap life science firms, Smith and the Mann Bioinvest team continue to see significant value in small-cap and private life science companies where greater diligence is needed to determine value. Furthermore, many life science funds previously investing in small-cap and private companies have withdrawn as the market has become increasingly focused on larger, listed companies. Unlike its sister fund MBIF, MBP will be investing for growth not income. It will deploy a cross-over strategy, ready to invest at all but the earliest (and most risky) stages of drug development. Fund size will be £100 million, with a minimum investment of £1,000,000. Strong Pipeline of Innovative Companies MBP’s targets will be life science companies with innovative and specialty products with the greatest chance of clinical, regulatory and commercial success, including biotechnology, pharmaceuticals, medical devices and diagnostics. The team will deploy an activist approach where appropriate, and will tend to invest for the long term. The investment team has already identified a strong pipeline of potential opportunities and also benefits from deal-flow due to the global investor network of Jim Mellon. A Pedigree CIO Smith brings an extensive track record of life science investment expertise across multiple investment firms (including AXA Framlington Biotech Fund, Bioscience Investment Trust and International Biotechnology Trust), different technologies, various therapeutic areas and disparate geographies. With a PhD in molecular biology, Smith has direct industry experience working in R&D and commercial roles for companies such as ICI, Glaxo and SmithKlineBeecham Pharmaceuticals, including managing a successful pharmaceutical brand with £130 million in annual sales. He was awarded techMark Technology Fund Manager of the Year in 2007. When combined with the experience of the remaining investment team, this deep knowledge of science, investment, product development and marketing not only adds unique value to the selection process but also means MBP can provide strategic guidance and advice to investee companies to aid their growth. Capitalising on Demographic and Technological Momentum Although valuations in some parts of the sector may be reaching their peak in the short term, Smith, Mellon and the Mann Bioinvest team believe that, with demographic and technological momentum in its favour, the sector as a whole has major long-term potential. Skilled investors can extract extra value from a long-term approach to early-stage companies. “The fund stands to benefit from major secular changes, in particular the increasing incidence of lifestyle diseases associated with high-calorie diets, type-2 diabetes and the associated co-morbidities. This will compound the increasing social costs of an ageing population, in both developed and emerging economies, which are characterized by a rapidly deteriorating dependency ratio (the relationship of the non-working to working as the population ages). The predictable consequence will be an increased spend, both through private and public healthcare systems, on tools, techniques and treatments that will reduce suffering, enhance lifestyles and improve clinical outcomes,” says Smith. |
Posted at 13/8/2015 17:59 by kingston78 This is the type of shares that will attract the attention of investors when a transforming deal has been done. It is worth including this as part of your portfolio because one day the share price will shoot up without warning. Your patience will be rewarded. |
Posted at 10/8/2015 15:11 by jc111 Two Billionaires - Mr Greg Bailey and Mr Jim Mellon have acquired 29.9% of 3LEG - with remit to transform it into a Life Sciences Group/L.S Technologies and related industries.Why would Two Billionaires take Control of a £1m mk cap shell if they weren't a grander plan already in place to use the shell co as the basis for a new exciting Life Sciences Group. One Of The Most Intriguing Ground Floor Opportunities I've seen for a long time. Dr Greg Bailey - Co-Founder of $8.5 Billion quoted Medivation Inc and a Host of other Pharma's. Jim Mellon needs no introduction - A Billionaire who knows his onions in pretty much every new Technology that is coming through with a specific interest in the Pharma's and Life Sciences. Between these two Men, they control almost 30% of the Share Capital. They also have options that between them would push them above that take over threshold. For How long will this Remain a Tiny Shell capped at £1.2m? View Mr Mellon's excellent speech at Master Investor and I don't think there will be much waiting around, he certainly isn't the type. 3LEG - ISDX TRADES : - Please put relevant articles for discussion and keep this a friendly investor board. Thread started 10.08.2015 - share price 0.28p MK CAP £1.2m |
Posted at 24/7/2015 09:55 by 5baggersrus AGM to vote on the new investment proposal is next week .... in reality it is a forgone conclusionSince the time passed from Mellon and Co coming on board .... expecting news to follow soon after the AGM A decent punt as currently valued around cash .... Mellon is a decent honest guy that has a level of integrity most AIM directors and investors lack .... hence I am happy to invest on the back of his buying in here Small stake for now as it is still just a shell but will happily average up as plans unfold ..... good luck |
Posted at 30/3/2015 10:51 by moreforus Sherl0ckPosts: 1,908 Premium Chat Member Off Topic Opinion: No Opinion Price: 0.30 Confirmed Today 10:46 To me by BoD back in Jan: "There is a specific deal that has been put in front of us - it appears an attractive proposition but clearly one cannot take it forward until the shell transaction is complete". The shell transaction was indeed completed at the time of the Feb placing when money was returned to previous investors and this turned into a completely clean shell. And now we simply await the RTO (was also mentioned to me that it's an RTO here rather than investment) |
Posted at 02/9/2014 10:05 by 8craggle HOUSTON – ConocoPhillips (NYSE: COP) today announced that Ryan Lance, chairman and CEO, will speak to investors and securities analysts at the Barclays CEO Energy-Power Conference in New York City on Wednesday, Sept. 3 at 9:05 a.m. EDT.This presentation will include an overview of the company's business strategies, key programs and projects, and plans for delivering production and margin growth. Investors can access a live audio webcast of the presentation at www.conocophillips.c This hopefully will touch on the polish plays tomorrow. |
Posted at 18/8/2014 18:55 by linksdean Poland 'Bubbles Up' as Marathon Target for Next Shale-Gas Boom By Katarzyna Klimasinska - December 9, 2009 01:00 EST Dec. 9 (Bloomberg) -- ConocoPhillips and Marathon Oil Corp. are betting that Poland, which gets half of its natural gas from Russia, can yield a development boom in shale formations like those that drove a jump in U.S. output of the heating fuel. The third- and fourth-biggest U.S. oil companies obtained exploration licenses this year covering hundreds of thousands of acres in Poland. The country, which imports 72 percent of its gas, could become an exporter of the fuel, said Maciej Wozniak, chief adviser on energy security to Prime Minister Donald Tusk. "Everything leads to a conclusion that in four or five years, and this is how much time we have to prepare for this, Poland will become a place with quite a lot of gas," Wozniak said in a telephone interview. Shale developments, where rock formations are fractured and injected with water and sand to release trapped fuel, account for about 15 percent of U.S. gas output, according to Oklahoma City-based Chesapeake Energy Corp. After successes in the U.S., producers such as Houston-based Marathon seek to exploit similar geological formations around the world. "We looked at a number of countries in Europe and through Asia," Marathon Executive Vice President David Roberts told investors in a Nov. 19 presentation after the company obtained its license. "Poland bubbled up to the top of our list." Russia Reliance Shale projects contributed to a drop in U.S. gas prices from a 2008 high of $13.69 per million British thermal units to a 2009 average of about $4.06. Successful drilling wouldn't end Poland's reliance on Moscow-based OAO Gazprom, which disrupted gas supplies to 20 European nations in January on a price dispute with Ukraine. Poland's gas-distribution monopoly, Polskie Gornictwo Naftowe i Gazownictwo SA, agreed Nov. 3 to contract with Gazprom for almost three-fourths of its gas until 2037. The deal is pending approval by governments of both countries. "It would have no choice but to pay the price agreed to in the contract even if the price on the cash market falls due to additional supplies from the shale formations," said Vince Kaminski, an adjunct professor at Rice University in Houston and former risk-management director at Enron Corp. Gas discoveries could enhance energy security for Poland and neighboring countries such as the Czech Republic and Slovakia. Polskie Gornictwo, based in Warsaw, cut sales to the nation's largest refiner, PKN Orlen SA, and the biggest fertilizer maker, Zaklady Azotowe Pulawy SA, after the Russian-Ukrainian conflict left Poland with limited supplies. Energy Security "Increasing natural-gas production in Poland, especially in such a sustainable way, is very important for us," Wozniak said. "Given our situation and the problems we had over the last years with securing stable supply on the gas market in the country, this initiative is particularly valuable." Polish shale gas is "a long way off" from having a "serious" impact, Gazprom said in a statement. Long-term contracts are needed for gas users to secure supplies and for producers to finance infrastructure projects, the company said. Polskie Gornictwo, which produces about 4.1 billion cubic meters of gas a year in Poland, plans to drill in shale formations with Marathon and Chevron Corp., said Piotr Gliniak, the company's exploration director. It may turn out that Polish shale formations have too much water to tap using techniques currently employed in the U.S., he said. "It seems to me that at the moment, the foreign companies are a bit too optimistic about what may be found in Poland," Gliniak said. Silurian Shale Representatives of Marathon and ConocoPhillips of Houston declined to comment for this article. If the 430 million-year-old Silurian shale that stretches through Poland proves to be "an economic resource," 48 trillion cubic feet (1.4 trillion cubic meters) of gas could be recovered over decades, according to Rhodri Thomas, a project adviser at Wood Mackenzie Ltd. in Edinburgh. That much gas would sell for more than $240 billion at current futures prices. ConocoPhillips has an option to develop as many as 1 million acres in the Silurian shale under an exploration agreement with Warsaw-based Lane Energy, the U.S. company said in a Sept. 9 presentation to investors. The companies plan to drill the first well near the northern Polish town of Lebork, said Kamlesh Parmar, country manager at Lane Energy. Parmar said the concession area has all the geological attributes, including a thick and organically rich rock formation, to become a successful shale-gas development. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
